-- Addresses the introduction of Betaseron as the first drug approved by the FDA
for treatment of some patients with MS
-- Assesses the results of new clinical trials with other interferons, Cop-1,
and oral myelin
-- Contains expanded information on the use of antidepressants, such as Prozac,
to combat psychological effects
-- Discusses laws that help individuals with MS avoid discrimination in
employment
-- Outlines recent findings in epidemiology and genetics
-- Includes patient resources